

Consolidated Financial Statements

Quest PharmaTech Inc.

Nine months ended October 31, 2013

(Unaudited)

Quest PharmaTech Inc.

National Instrument 51 – 102
Continuous Disclosure Obligations

Notice

Pursuant to Part 4.3 (3) of National Instrument 51 – 102, these unaudited interim consolidated financial statements of Quest PharmaTech Inc. for the nine month period ended October 31, 2013 have not been reviewed by the Company's auditors.

Quest PharmaTech Inc.**CONSOLIDATED STATEMENTS OF FINANCIAL POSITION**
(see note 1 – going concern uncertainty)

As at

	Oct 31, 2013 (Unaudited) \$	Jan 31, 2013 (Audited) \$
ASSETS		
Current		
Cash	239,850	56,637
Accounts receivable	6,068	36,974
Prepaid expenses	33,678	25,582
	279,596	119,193
Non current		
Property and equipment <i>[note 4]</i>	53,244	64,513
Intangibles <i>[note 3]</i>	41,710	59,524
	94,954	124,037
	374,550	243,230
LIABILITIES		
Current		
Accounts payable and accrued liabilities	625,596	679,783
Demand loans <i>[note 10]</i>	870,000	870,000
Interest free loan <i>[note 10]</i>	—	500,000
Convertible debenture <i>[note 5]</i>	—	400,000
	1,495,596	2,449,783
SHAREHOLDERS' DEFICIENCY		
Common shares <i>[note 6]</i>	25,213,875	24,623,875
Shares to be issued <i>[note 6]</i>	—	500,000
Warrants <i>[note 6]</i>	—	200,000
Equity portion of convertible debenture	—	60,000
Contributed surplus	2,252,965	1,916,715
Contributed Surplus – Investment financing <i>[note 15]</i>	3,560,000	1,100,000
Deficit	(32,147,886)	(30,607,143)
	(1,121,046)	(2,206,553)
	374,550	243,230

See accompanying notes

Quest PharmaTech Inc.

**CONSOLIDATED STATEMENTS OF
LOSS AND COMPREHENSIVE LOSS**

	For the three months ended October 31		For the nine months ended October 31	
	2013	2012	2013	2012
	\$	\$	\$	\$
REVENUE	—	—	—	—
EXPENSES				
General and administrative	130,153	149,503	441,158	466,237
Research and development, net <i>[note 14]</i>	372,771	244,207	1,014,340	606,941
	502,924	393,710	1,455,498	1,073,178
Loss before the undernoted	(502,924)	(393,710)	(1,455,498)	(1,073,178)
Other income (expense)				
Financial income	89	462	154	679
Financial expenses <i>[notes 5 and 10]</i>	(18,823)	(31,674)	(79,392)	(97,500)
Foreign exchange gain (loss)	(3,569)	(7,218)	(6,007)	(5,455)
	(22,303)	(38,430)	(85,245)	(102,276)
Net and comprehensive loss for the period	(525,227)	(432,140)	(1,540,743)	(1,175,454)
Basic and diluted loss per share	(\$0.006)	(\$0.005)	(\$0.018)	(\$0.014)

See accompanying notes

Quest PharmaTech Inc.

CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' DEFICIENCY

	Share Capital \$	Equity portion of convertible debenture \$	Shares to be issued \$	Warrants \$	Contributed surplus \$	Contributed surplus – investment financing \$	Deficit \$	Total Shareholders' Deficiency \$
Balance, February 1, 2012	24,598,875	60,000	—	200,000	1,830,365	—	(28,976,976)	(2,287,736)
Common shares issued/issuable [note 6]	25,000	—	500,000	—	—	—	—	525,000
Share based compensation [note 8]	—	—	—	—	86,350	—	—	86,350
Net loss for the period	—	—	—	—	—	—	(1,175,454)	(1,175,454)
Balance, October 31, 2012	24,623,875	60,000	500,000	200,000	1,916,715	—	(30,152,430)	(2,851,840)
Balance, February 1, 2013	24,623,875	60,000	500,000	200,000	1,916,715	1,100,000	(30,607,143)	(2,206,553)
Common shares issued/issuable [note 6]	590,000	—	(500,000)	—	—	(90,000)	—	—
Funding received [note 15]	—	—	—	—	—	2,050,000	—	2,050,000
Conversion of interest free loan [note 10]	—	—	—	—	—	500,000	—	500,000
Balance transfer	—	(60,000)	—	—	60,000	—	—	—
Expiry of Warrants [note 6]	—	—	—	(200,000)	200,000	—	—	—
Share based compensation [note 8]	—	—	—	—	76,250	—	—	76,250
Net loss for the period	—	—	—	—	—	—	(1,540,743)	(1,540,743)
Balance, October 31, 2013	25,213,875	—	—	—	2,252,965	3,560,000	(32,147,886)	(1,121,046)

See accompanying notes

Quest PharmaTech Inc.

CONSOLIDATED STATEMENTS OF CASH FLOWS

	For the three months ended October 31		For the nine months ended October 31	
	2013	2012	2013	2012
	\$	\$	\$	\$
CASH FLOWS FROM (USED IN) OPERATING ACTIVITIES				
Net loss for the period	(525,227)	(432,140)	(1,540,743)	(1,175,454)
Add (deduct) items not involving cash				
Amortization	10,288	27,368	32,702	80,098
Share-based compensation <i>[note 8]</i>	6,750	48,750	76,250	86,350
Net changes in working capital <i>[note 11]</i>	68,129	(17,037)	(31,377)	(252,547)
NET CASH FLOWS FROM (USED IN) OPERATING ACTIVITIES	(440,060)	(373,059)	(1,463,168)	(1,261,553)
CASH FLOWS FROM (USED IN) FINANCING ACTIVITIES				
Increase in demand and other loans <i>[note 10]</i>	—	—	200,000	534,000
Repayment of demand loans	—	(50,000)	(200,000)	(124,000)
Repayment of convertible debenture <i>[note 5]</i>	—	(100,000)	(400,000)	(100,000)
Private placement proceeds <i>[note 6]</i>	—	—	—	500,000
Investment agreement funding <i>[note 15]</i>	—	600,000	2,050,000	600,000
NET CASH FLOWS FROM (USED IN) FINANCING ACTIVITIES	—	450,000	1,650,000	1,410,000
CASH FLOWS FROM (USED IN) INVESTING ACTIVITIES				
Purchase of property and equipment	—	—	(3,619)	(4,906)
Purchase of IgE technology <i>[note 3]</i>	—	(38,892)	—	(38,892)
NET CASH FLOWS FROM (USED IN) INVESTING ACTIVITIES	—	(38,892)	(3,619)	(43,798)
Net (decrease) increase in cash and cash equivalents	(440,060)	38,049	183,213	104,649
Cash and cash equivalents, beginning of period	679,910	141,575	56,637	74,975
Cash and cash equivalents, end of period	239,850	179,624	239,850	179,624

See accompanying notes

Quest PharmaTech Inc.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

For the nine months ended October 31, 2013

1. CORPORATE INFORMATION AND GOING CONCERN UNCERTAINTY

Corporate information

Quest PharmaTech Inc. (the “Company”) is a biotechnology company committed to the development and commercialization of oncology product candidates. It is developing a series of products for the treatment of cancer based on its pipeline of SonoLight compounds and monoclonal antibodies which target certain tumor antigens that are presented in a variety of cancers. The Company believes that by combining these antibodies with other cancer therapies such as chemotherapy, photodynamic therapy or radioimmuno therapy, it can potentially further complement and enhance treatment outcomes compared to antibody treatment alone.

The Company is incorporated under the Business Corporations Act (Alberta). The Company’s functional currency is the Canadian dollar. The principal address of the Company is 8123 Roper Road NW, Edmonton, Alberta, T6E 6S4.

The Company is publicly traded on the TSX Venture Exchange under the symbol “QPT”.

Going concern uncertainty

The Company’s consolidated financial statements have been prepared on a going concern basis which presumes the realization of assets and discharge of liabilities in the normal course of business for the foreseeable future. The Company has experienced significant operating losses and cash outflows from operations since its inception.

The Company has incurred a net loss of \$ 1,540,743 for the nine months ended October 31, 2013 and as at October 31, 2013 had a working capital deficiency of \$1,216,000 (January 31, 2013 - \$2,330,590) and a shareholders’ deficiency of \$1,121,046 (January 31, 2013 - \$2,206,553). Accordingly, there is a material uncertainty that may cast significant doubt regarding the Company’s ability to continue as a going concern.

Quest PharmaTech Inc.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

For the nine months ended October 31, 2013

1. CORPORATE INFORMATION AND GOING CONCERN UNCERTAINTY [CONTINUED]

The Company's ability to continue as a going concern is uncertain and is dependent upon its ability to raise additional capital to successfully complete its research and development programs, commercialize its technologies, conduct clinical trials and receive regulatory approvals for its products. It is not possible at this time to predict the outcome of these matters. The Company's consolidated financial statements do not reflect any adjustments to the classifications and carrying values of assets and liabilities that may be required should the Company be unable to continue as a going concern and therefore be required to realize its assets and discharge its liabilities in other than the normal course of business. The Company intends to address this uncertainty through the Investment Financing agreements (note 15) and also through issuing new share capital through equity financing, licensing arrangements and/or strategic partnerships.

2. BASIS OF PREPARATION

The unaudited consolidated financial statements of the Company were prepared following the same accounting policies as disclosed in Note 3 in the audited consolidated financial statements for the years ended January 31, 2013 and 2012. These unaudited consolidated financial statements for the nine months ended October 31, 2013 should be read in conjunction with the consolidated financial statements for the years ended January 31, 2013 and 2012 and the notes thereto. These unaudited consolidated financial statements for the nine months ended October 31, 2013 do not include all of the required disclosures for annual consolidated financial statements.

Statement of Compliance

These consolidated financial statements have been prepared by management in accordance with IAS 34 "Interim Financial Reporting" using accounting principles consistent with International Financial Reporting Standards ("IFRS") issued by the International Accounting Standards Board ("IASB").

These consolidated financial statements were approved and authorized for issuance by the Board of Directors on December 6, 2013.

Basis of measurement

The consolidated financial statements have been prepared under the historical cost convention with the exception of financial instruments which have been measured at fair value.

Quest PharmaTech Inc.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

For the nine months ended October 31, 2013

3. INTANGIBLE ASSETS

	October 31, 2013		January 31, 2013	
	Cost \$	Accumulated amortization \$	Cost \$	Accumulated amortization \$
IgE technology	63,892	22,182	63,892	6,212
Immunotherapy technology	237,500	237,500	237,500	235,656
Hypocrellin based technology and licenses	2,476,822	2,476,822	2,476,822	2,476,822
CDK technology	225,000	225,000	225,000	225,000
	3,003,214	2,961,504	3,003,214	2,943,690
Net book value	41,710		59,524	

During the three and nine months ended October 31, 2013, amortization of intangible assets was \$5,324 and 17,814, respectively (2012 – \$20,680 and \$60,263, respectively).

CORE TECHNOLOGIES

AllergoOncology technology and licenses (“IgE technology”)

During September, 2012, the Company signed a technology purchase agreement with Advanced Immune Therapeutics, Inc. (“AIT”) to acquire the proprietary rights and intellectual property related to an allergo-oncology technology based on tumor associated Immunoglobulin E (IgE) antibody for the treatment of cancer. Under the terms of the agreement, consideration for the purchase consisted of payment of \$40,000 U.S. for past patent costs and the issuance of 500,000 common shares, valued for accounting purposes at \$0.05 per common share which reflected the closing price of the common shares on the date of issuance (\$25,000). The agreement requires the Company to make milestone and royalty payments to AIT on future revenues. The Company is amortizing this asset on a straight-line basis over a three year period.

Immunotherapy technology and licenses (“Immunotherapy technology”)

During September, 2009, the Company signed a technology purchase agreement with Paladin Labs Inc. (“Paladin”) to acquire the proprietary rights and intellectual property related to an antibody immunotherapy technology. Under this technology, the Company acquired product candidates consisting of five monoclonal antibodies targeting certain tumor antigens that are presented in a variety of cancers. Under the terms of the agreement, consideration for the purchase consisted of a cash payment of \$37,500 and the issuance of 1,500,000 common shares upon the effective date of the purchase and an additional 1,500,000 common shares to be issued no later than December 31, 2010. The common shares issued on the effective date and those issued prior to December 31, 2010 were valued for accounting purposes at \$0.04 per share which reflected the closing price of

Quest PharmaTech Inc.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

For the nine months ended October 31, 2013

3. INTANGIBLE ASSETS [CONTINUED]

the common shares on the effective date of the purchase (\$60,000 and \$60,000 respectively). Under the terms of the agreement a further 2,000,000 common shares were contingently issuable upon successful future financing initiatives by the Company. On October 22, 2010, the Company decided to take control over the technology and issued the final 3,500,000 common shares under the agreement. The 2,000,000 common shares issued on October 22, 2010 reflecting the contingent consideration were valued for accounting purposes at \$0.04 per share which reflected the closing price of the common shares at that date (\$80,000). The agreement also requires the Company to make milestone and royalty payments to Paladin on future revenues. This intangible asset is fully amortized.

Hypocrellin-based technology and licenses (proprietary rights)

The Company's subsidiary, Sonolight, holds the exclusive worldwide license to develop, commercialize and exploit several proprietary inventions involving a class of sonosensitizers and their use in cancer and non-cancer therapies. Sonolight signed a licensing agreement dated March 6, 2001 with the University of Alberta. The license agreement is for a term of 25 years. The agreement requires royalty payments upon successful sales and marketing of products developed using the technology. The Company has amortized this asset on a straight-line basis over a three-year period that commenced August 1, 2001. This intangible asset is fully amortized.

NON-CORE TECHNOLOGIES (CDK technology (proprietary rights))

The Company owns the worldwide rights to develop, manufacture and sell the CDK technology, a novel immunomodulator with anti-cancer properties. As consideration for its acquisition of the technology, the Company must issue 400,000 common shares as certain milestones outlined in the technology purchase agreement are met. To date, the Company has issued 200,000 shares under the agreement: 100,000 shares issued in fiscal 2004 and 100,000 shares in fiscal 2003. These shares have been recorded at a value that represents the closing price of the common shares on the date the shares were issued. The Company amortized this asset on a straight-line basis over a three-year period, which commenced on August 1, 2002. This intangible asset is fully amortized. During fiscal 2009, the Company determined that it will not proceed with further development with respect to the CDK technology.

Quest PharmaTech Inc.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

For the nine months ended October 31, 2013

4. PROPERTY AND EQUIPMENT

	October 31, 2013		January 31, 2013	
	Cost \$	Accumulated amortization \$	Cost \$	Accumulated amortization \$
Computer equipment	82,149	78,197	82,149	77,049
Furniture and fixtures	12,114	11,855	12,114	11,779
Office equipment	31,494	31,076	31,494	30,954
Manufacturing and research and development equipment	457,983	413,235	456,084	400,521
Leasehold improvements	5,220	1,353	5,805	2,830
	588,960	535,716	587,646	523,133
Net book value		53,244		64,513

During the three and nine months ended October 31, 2013, amortization of property and equipment was \$4,963 and \$14,888, respectively (2012 - \$6,687 and \$19,834, respectively).

5. CONVERTIBLE DEBENTURE

On March 23, 2005, the Company entered into an agreement to issue a \$1,000,000 principal amount 8% convertible debenture with a one-year maturity to two arm's-length parties. The debenture was collateralized by the Company's Hypocrellin-based technology, one of its core technologies (note 3). The debenture was repayable in blended monthly installments of \$6,667 with the balance, including accrued interest, due on March 22, 2006. The debenture had a conversion feature whereby it could be converted into common shares of the Company at a price of \$0.45 per common share and could be redeemed at any time by the Company. In connection with the extensions the debenture interest rate was revised from 8% to 9% per annum and the debenture conversion price was amended from \$0.45 to \$0.25 per common share. During 2008, the Company made principal payments of \$500,000 against the convertible debenture. During fiscal 2013, the Company made a principal payment of \$100,000 against the convertible debenture. During the six month period ended July 31, 2013, the Company made a principal payment of \$400,000 against the convertible debenture which is now repaid in full.

During the three and nine months ended October 31, 2013, the Company incurred \$nil and \$18,000, respectively (2012 - \$11,250 and \$22,500, respectively) in interest under this convertible debenture.

Quest PharmaTech Inc.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

For the nine months ended October 31, 2013

6. SHARE CAPITAL

Authorized

Unlimited number of common shares without nominal or par value

Unlimited number of first preferred shares

Unlimited number of second preferred shares

The first and second preferred shares may be issued in one or more series and the directors are authorized to fix the number of shares in each series and to determine the designation, rights, privileges, restrictions and conditions attached to the shares of each series.

Issued

	Number of common shares	Amount \$
Common shares		
At January 31, 2012	83,197,580	24,598,875
Shares issued pursuant to a technology purchase	500,000	25,000
At January 31, 2013	83,697,580	24,623,875
Shares issued pursuant to a private placement	5,000,000	500,000
Shares issued pursuant to the Investment Financing	3,000,000	90,000
At October 31, 2013	91,697,580	25,213,875

In October, 2013, the Company issued 3,000,000 common shares under the Investment Financing (note 15). The shares were valued at \$0.03 per share which represented the closing price of the common shares on the date of issue. The Company recorded this transaction as an increase in share capital and a reduction of Contributed Surplus - Investment financing.

In October, 2013, the Company issued 5,000,000 common shares pursuant to a May 2012 \$500,000 private placement.

In October, 2012, the Company issued 500,000 common shares to acquire the IgE technology. The 500,000 shares were valued at \$0.05 per common share which represented the closing price of the common shares on the date of issue.

Quest PharmaTech Inc.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

For the nine months ended October 31, 2013

6. SHARE CAPITAL [CONTINUED]

The following options to purchase common shares were outstanding as at October 31, 2013:

Exercise price \$	Options outstanding #	Weighted average remaining life (years)	Options exercisable #
0.10	8,890,000	7.61	8,890,000
0.15	450,000	0.01	450,000
	9,340,000	7.62	9,340,000

The following schedule details the warrants and share-based payment transactions granted and expired:

	Shares issuable on exercise of			
	Warrants		Share options	
	Number of shares #	Weighted average exercise price \$	Number of shares #	Weighted average exercise price \$
Balance, January 31, 2012	10,000,000	0.10	6,475,000	0.13
Granted	—	—	1,915,000	0.10
Expired	—	—	(1,475,000)	0.23
Balance, January 31, 2013	10,000,000	0.10	6,915,000	0.10
Granted	—	—	2,475,000	0.10
Expired	(10,000,000)	(0.10)	(50,000)	0.23
Balance, October 31, 2013	—	—	9,340,000	0.10

Warrants

In October 2011, the Company issued 10,000,000 share purchase warrants exercisable at \$0.10 per common share pursuant to a private placement of units. The warrants were valued at \$0.02 per warrant using the Black-Scholes option valuation model with the following assumptions (dividend rate – 0.00%, volatility – 151.7%, risk-free interest rate – 1.20%, expected life – 2 years). The warrants expired on October 25, 2013.

Quest PharmaTech Inc.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

For the nine months ended October 31, 2013

6. SHARE CAPITAL [CONTINUED]

Share options

For the three and nine month period ended October 31, 2013, the Company granted 25,000 and 2,475,000 share options, as per the Company's Share Option Plan. These share options have exercise prices ranging from \$0.10 to \$0.15. 2,050,000 share options were granted to employees and 425,000 to non-employees (note 8).

For the three and nine month period ended October 31, 2012, the Company granted 975,000 and 1,915,000 share options, as per the Company's Share Option Plan. These share options have an exercise price of \$0.10. 940,000 were granted to employees and 975,000 to non-employees (note 8).

On July 26, 2012, the Company obtained shareholder approval to amend its share option plan such that the aggregate number of common shares eligible for issuance under the Share Option Plan shall not exceed 12,000,000. At October 31, 2013, 2,660,000 options are available for issue.

Basic and diluted loss per share

Basic loss per share has been calculated using the weighted average number of common shares outstanding during the period (2013 – 84,574,292; 2012 – 83,218,128). For the periods presented, the calculation of loss per common share on a diluted basis excluded all potential common shares because the effect was anti-dilutive.

7. CAPITAL DISCLOSURES

The Company is a biotechnology company and consistent with other companies in the industry, the Company's objectives when managing capital are to safeguard its accumulated capital in order to maintain its ability to continue as a going concern so that it can continue with its drug development program and strive to maximize shareholder value. Note 1 provides a discussion surrounding the Company's ability to continue as a going concern. Capital is defined by the Company as shareholders' deficiency (primarily comprised of share capital, contributed surplus and deficit) and current term debt consisting of demand loans. The Company manages its capital structures, and makes adjustments to it based on the needs of the Company's operations and the requirement for funding to continue with the Company's drug development program. The Company does this through new share or debt issuances, selling assets or licensing its technologies to third parties to fund operations. The Company is not subject to any externally imposed capital requirements.

Quest PharmaTech Inc.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

For the nine months ended October 31, 2013

8. SHARE-BASED PAYMENTS

For the three and nine months ended October 31, 2013, the Company granted a total of 25,000 and 2,475,000, respectively (2012 – 975,000 and 1,915,000, respectively) share options under the Company's Share Option Plan. The fair value of options vesting in 2013 of \$6,750 and \$76,250, respectively (2012 - \$48,750 and \$86,350, respectively) was recognized as a share-based payment expense and credited to contributed surplus for the three and nine months ended October 31, 2013 and 2012. There were no forfeitures of the Company's share options during the three and nine months ended October 31, 2013 and 2012.

The Company used the Black-Scholes option pricing model to estimate the fair value of these options. The Company considers historical volatility of its common shares in estimating future share price volatility. The following assumptions were used:

Nine months ended October 31	2013	2012
	\$	\$
Dividend yield	0.00%	0.00%
Volatility	145.6 – 146.5%	143.7 – 145.4%
Risk-free interest rate	2.20 – 2.63%	1.75 - 1.88%
Expected life (years)	10	10
Fair value per option	\$0.03-\$0.04	\$0.04-\$0.05

9. SEGMENT DISCLOSURES

The Company is managed as one operating segment – biopharmaceutical/pharmaceutical products. Management assesses performance and makes resource decisions based on the consolidated results of operations of this operating segment. Substantially all of the operations of the Company are directly engaged in or support this operating segment. There was no revenue earned for the three and nine months ended October 31, 2013 and 2012.

Quest PharmaTech Inc.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

For the nine months ended October 31, 2013

10. DEMAND LOANS, INTEREST FREE LOAN AND RELATED PARTY TRANSACTIONS

During the year ended January 31, 2011, the Company entered into a demand loan agreement with one of its officers to provide up to \$1,000,000 bearing interest at 8% compounded annually to be used for the Company's operating expenditures. This financing is unsecured, with principal repayment to be made 30 days after demand and interest is payable monthly. As at October 31, 2013, the Company had drawn \$680,000 on this financing. During the year ended January 31, 2012, the Company secured additional demand loan financing of \$100,000 from a director of the Company. This demand loan financing bears interest at 8% per annum, interest payable monthly and is unsecured with principal repayment to be made 30 days after demand. As at October 31, 2013, the Company had demand loan financing of \$90,000 from an officer of the Company. This demand loan financing bears interest at 8% per annum, interest payable monthly and is unsecured with principal repayment to be made 30 days after demand. During fiscal 2013, the Company received \$500,000 in an interest free loan from an insider of the Company. During the three month period ended July 31, 2013, these funds were converted into a part of the investment financing (note 15). During the three and nine month periods ended October 31, 2013, the Company incurred \$17,543 and \$57,350, respectively (2012 – \$19,070 and \$59,489, respectively) in interest under the demand loan financing, \$17,543 and \$52,057, respectively, with related parties (2012 – \$17,520 and 52,404, respectively).

11. SUPPLEMENT CASH FLOW INFORMATION

NET CHANGE IN NON-CASH WORKING CAPITAL ITEMS RELATED TO OPERATING ACTIVITIES

	Three months ended October 31		Nine months ended October 31	
	2012	2011	2012	2011
	\$	\$	\$	\$
Accounts receivable	28,613	26,500	30,906	(1249)
Prepaid expenses	(4,351)	(153)	(8,096)	1452
Accounts payable and accrued liabilities	43,867	(43,384)	(54,187)	(252,750)
	68,129	(17,037)	(31,377)	(252,547)

Quest PharmaTech Inc.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

For the nine months ended October 31, 2013

12. FINANCIAL INSTRUMENTS AND RISK MANAGEMENT

The Company's financial instruments include cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities, and the demand loans.

a) Carrying value and fair value

The carrying values of cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities, and the demand loans approximate their fair value due to the immediate or short term maturity of these financial instruments. The fair value of the Company's financial instruments of cash and cash equivalents are measured using the Level 1 classification of the fair value hierarchy.

b) Risks

i) Foreign currency risk

The Company has certain assets and liabilities that are denominated in foreign currencies and are exposed to risks from changes in foreign exchange rates and the degree of volatility of these rates. Due to the limited number of transactions that are denominated in foreign currencies, the Company does not consider its exposure to foreign currency risk to be significant and currently does not use derivative instruments to reduce its exposure to this.

ii) Liquidity risk

Liquidity risk is the risk that the Company will not be able to meet its financial obligations as they become due. The Company's exposure to liquidity risk is dependent on its ability to raise funds to meet its commitments and sustain its operations. The Company controls liquidity risk by managing its working capital and by securing additional funds through equity, debt or partnering transactions (see Capital Disclosures, note 7). In fiscal 2013 and 2014, the Company secured debt financing from its officers, from a director and from unrelated third parties to provide demand loan financing for operational expenditures. During Fiscal 2013, the Company closed a private placement and received an interest free loan. During Fiscal 2014, the Company received investment financing from related parties.

iii) Credit risk

Financial instruments that subject the Company to credit risk consist primarily of cash and cash equivalents and accounts receivable. To minimize its exposure to credit risk for cash equivalents, the Company invests surplus cash in short-term deposits that are fully guaranteed by the Company's financial banker, a major Canadian bank. As the Company is a research and development company, the Company's exposure to credit risk related to accounts receivable is not considered to be significant. At year end, 100% of accounts receivable were due from one federal government agency.

Quest PharmaTech Inc.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

For the nine months ended October 31, 2013

12. FINANCIAL INSTRUMENTS AND RISK MANAGEMENT [CONTINUED]

iv) Interest rate risk

Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates.

Financial assets and financial liabilities with variable interest rates expose the Company to cash flow interest rate risk. The Company's cash and cash equivalents are comprised of highly liquid deposits or investments that earn interest at market rates. Interest on the demand loans is at fixed rates. Consequently, the Company is exposed to fair value changes on long-term debt when the market interest rate changes. Accounts receivable, accounts payable and accrued liabilities bear no interest.

The Company manages its interest rate risk by maximizing the interest income earned on excess funds while maintaining the liquidity necessary to conduct operations on a day-to-day basis. The Company's policy limits the investing of excess funds to liquid government guaranteed deposits or guaranteed investment certificates.

13. COMPENSATION OF KEY MANAGEMENT

Key management includes directors and executives of the Company. The compensation paid or payable (including stock based compensation) to key management for services is shown below:

	Three months ended October 31		Nine months ended October 31	
	2013	2012	2013	2012
	\$	\$	\$	\$
Salaries and short term employee benefits	94,000	94,000	327,000	301,600
Director compensation	—	—	16,500	18,000
	94,000	94,000	343,500	319,600

Quest PharmaTech Inc.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

For the nine months ended October 31, 2013

14. GOVERNMENT ASSISTANCE

During the three and nine month periods ended October 31, 2012, the Company recognized amounts from Alberta Finance related to scientific research and development claims made for research and development expenditures incurred in fiscal 2012. This funding was treated as a reduction of research and development expenses.

	Three months ended October 31		Nine months ended October 31	
	2013	2012	2013	2012
	\$	\$	\$	\$
Gross R & D expenditures	372,771	244,207	1,014,340	629,990
Less government assistance	—	—	—	(23,049)
R & D expenditures, net	372,771	244,207	1,014,340	606,941

15. INVESTMENT FINANCING

During fiscal 2013, the Company signed an investment agreement with a related party to provide the Company with up to \$8,000,000 of funding over a 12 month period to support the Company's clinical trial programs and for operational expenditures. Under the investment agreement, the Company is required to issue up to 15,000,000 common shares and share up to 50% of future net revenues derived from the Company's immunotherapy and prostate cancer programs as funding milestones under the agreement are met. During fiscal 2013, the Company received \$1,100,000 of funding under the agreement. During the nine months ended October 31, 2013, the Company received a further \$50,000 of funding under the agreement. The Company recorded this funding as contributed surplus on the statements of financial position. During the nine months ended October 31, 2013, the \$500,000 interest free loan was converted into a part of the investment financing. In October, 2013, the Company issued 3,000,000 common shares pursuant to this investment agreement. The shares were valued at \$90,000 and the Company recorded this transaction as a reduction of contributed surplus.

During the nine months ended October 31, 2013, the Company entered into a strategic relationship with a third party to provide up to \$12,000,000 of clinical development funding in return for Quest common shares and future revenue sharing. The Company has received \$2,000,000 of funding under this agreement which has been recorded as contributed surplus on the statements of financial position.

Quest PharmaTech Inc.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

For the nine months ended October 31, 2013

16. SUBSEQUENT EVENTS

Subsequent to period end, the Company received \$300,000 under a \$1,000,000 private placement of 10,000,000 units at \$0.10 per unit. Each unit is comprised of one common share and one share purchase warrant. Each warrant is exercisable into one common share at a price of \$0.15 per share. The warrants carry a two year expiry.